How vigorous should we be in trying to lower LDL-C in patients who have statin intolerance? What is the role of combined—so-called “backbone”—statin treatment plus PCSK9 inhibitor therapy?

How vigorous should we be in trying to lower LDL-C in patients who have statin intolerance? What is the role of combined—so-called “backbone”—statin treatment plus PCSK9 inhibitor therapy?

How vigorous should we be in trying to lower LDL-C in patients who have statin intolerance? What is the role of combined—so-called “backbone”—statin treatment plus PCSK9 inhibitor therapy?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Erik S.G Stroes, MD, PhD

Erik S.G Stroes, MD, PhD

Professor Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands